Skip to main content

Advertisement

Log in

Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3

References

  1. Falini B . Anaplastic large-cell lymphoma: pathological, molecular and clinical features. Br J Haematol 2001; 114: 741–760.

    Article  CAS  Google Scholar 

  2. Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 2000; 96: 1605–1607.

    CAS  PubMed  Google Scholar 

  3. Mussolin L, Pillon M, d’Amore SG, Santoro N, Lombardi A, Fagioli F et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large-cell lymphoma. Leukemia 2005; 19: 1643–1647.

    Article  CAS  Google Scholar 

  4. Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2007; 110: 670–677.

    Article  CAS  Google Scholar 

  5. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G et al. Anaplastic large cell lymphoma (ALCL) in children: equal efficacy but greater toxicity of chemotherapy including methotrexate (MTX) 1g/m2 in 24 hour infusion with intra-thecal injection (IT) than chemotherapy with MTX 3g/m2 in 3 hours infusion without IT: results of the ALCL99-R1 randomised trial[abstract]. Blood 2006; 108: 122a.

    Google Scholar 

  6. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion transcripts for residual disease detection in leukaemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  Google Scholar 

  7. Ait-Tahar K, Bernardo MCN, Pulford K . CD4 T-Helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007; 67: 1898–1901.

    Article  CAS  Google Scholar 

  8. Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola N et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large-cell lymphomas. Haematologica 2006; 91: 48–55.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Fondazione Città della Speranza.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Rosolen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mussolin, L., Bonvini, P., Ait-Tahar, K. et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia 23, 400–402 (2009). https://doi.org/10.1038/leu.2008.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.184

  • Springer Nature Limited

This article is cited by

Navigation